Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Obesity Clinical Trials

A listing of Obesity medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (51) clinical trials

Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome

The investigators propose a phase 2 randomized double blind 8-week treatment trial of intranasal OXT vs. placebo in 50 subjects aged 5 to 17 years with PWS in order to assess IN-OXT's affect on measurements of (1) eating behaviors (2) repetitive behaviors (3) weight and body composition (4) quality of ...


A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity

The purpose of the study is to evaluate the efficacy, tolerability and safety of LIK066 to support dose selection for Phase 3 development in Japanese adults with obesity disease.


Mobile Attention Retraining in Overweight Female Adolescents

Over 30% of adolescents are overweight and 20% are obese, but the mechanisms that produce excessive weight gain in youth remain incompletely elucidated. Some overweight youth appear to have an attention bias (AB: a tendency to attend selectively to stimuli that have acquired salience or meaning) toward highly palatable food ...


The Effects of Oxytocin in Obese Adults

This is a randomized, double blind, placebo-controlled study of the effects of intranasal oxytocin in obese adults, ages 18-45 years old. Subjects will be randomized to receive of intranasal oxytocin or placebo (3 sprays per nostril, 4 times per day) for 8 weeks. Study visits include screening to determine eligibility, ...


Fecal Microbiota Transplantation for Diabetes Mellitus Type II in Obese Patients

Study design: 30 Patients will undergo 2 FMT's from a lean donor and will be randomized into 3 types of diet groups: low fat high fiber diet (20% fat) no change in fat intake (sham diet) high fat low fiber diet (40-45% fat) The treating physicians and the patients will ...


Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk

High adiposity is a major risk factor for a number of chronic diseases, including type 2 diabetes, cardiovascular diseases, and certain types of cancer, including postmenopausal breast cancer. The increased postmenopausal breast cancer risk in women with high adiposity is likely to be attributed to multiple metabolic disturbances including altered ...


Stool Transplantation for Treatment of Insulin Resistance in Morbidly Obese Patients

The coupled disorders of morbid obesity and type 2 diabetes (T2D) are a major and growing public health problem in Canada. The Public Health Agency of Canada 2011 report, Obesity in Canada, showed that 5.1% and 2.7% of Canadians had obesity class II (body mass index (BMI) 35.0-39.9) and III ...


Blood Lipopolysaccharide (LPS) Rifaximin Study

This is a randomized, placebo controlled proof of concept study that will examine the investigational drug Rifaximin Soluble Solid Dispersion (SSD) ability to reduce gut microbiota and thereby reduce adipose inflammation and improve insulin resistance. Each subject enrolled will undergo a fat tolerance test with a high fat meal, an ...


Ginger Capsules for the Chronic Treatment of Obesity

Overweight individuals will be interviewed at baseline and after 30, 60, 90, 120, 150 and 180 days from baseline. The following measures will be assessed: body composition (fat body% and free fat body%), anthropometric measures (height, weight, body mass index, waist circumference and abdominal circumference), blood pressure, basal metabolic rate, ...


Protocol Feasibility Study of HENRY

Background Childhood obesity impacts physiological and psychological health that tracks into adulthood; increasing risk of morbidity and mortality [1, 2]. It incurs significant costs on the UK economy, with an expected 7-fold increase in related NHS costs by 2020, and forecasted 2 billion annual spend by 2030[3]. Tackling obesity is ...